socalTECH

JULY 2, 2013

AddToAny , the developer of WordPress and Drupal social sharing plug-ins which got its start at UC San Diego, is back as an independent firm, according to the company''s founder, Pat Diven II. Diven said that he has acquired AddToAny back from Lockerz, which had acquired the company back in July of 2011. READ MORE>>.

UCSD 147

UCSD San Diego Blogging Acquisition 147

Xconomy

MAY 20, 2019

Yet another new biotech company has been founded in San Diego by serial entrepreneur Mike Grey and other alumni of rare disease startup Lumena Pharmaceuticals. Grey, who was president and CEO of Lumuna from 2011 through its 2014 acquisition by Irish drugmaker Shire (now part of Japan’s Takeda Pharmaceutical.

San Diego 88

San Diego Acquisition Entrepreneur Startup 88

Xconomy

JANUARY 7, 2020

When a group of scientists from Amira Pharmaceuticals wanted to start a new biotech after the company’s 2011 acquisition by Bristol-Myers Squibb , Celgene provided seed funding.

Seed Funding 63

Seed Funding Equity Research Acquisition 63

Xconomy

JULY 27, 2016

LabCorp will also assume net debt of San Diego-based Sequenom (NASDAQ: SQNM ), bringing the value of the cash deal to approximately $371 million. In 2011, state incentives lured the company to Research Triangle Park, where it built a $19 million lab to bolster its molecular diagnostics business. LabCorp reported $8.5

San Diego 40

San Diego .Net Report Sites 40

Xconomy

AUGUST 16, 2016

An obvious place to look for help is the venture community—Bruce Booth of Atlas Ventures pointed out in a recent blog that venture capital is doing well, and is positioned to do even better in the future. Yet despite relative plenty in the bio-venture community, pharma suffers from a shortage of drug candidates.

Product 40

Product Journal Venture Capital Demand 40

Xconomy

JULY 21, 2016

Biogen has been very deliberate in its dealmaking, reluctant to make a big splash with a large acquisition. Scangos wouldn’t rule out deals outside of neurology, but said the “bar gets higher” for an acquisition or partnership when it’s further removed from the company’s core expertise. Reprints | Share:

San Diego 40

San Diego Conference Pricing Acquisition 40

Xconomy

JULY 29, 2016

Some observers’ minds instantly jumped to business —Gilead needs to pick up the acquisition pace to find its next big thing. After all, Gilead’s $11 billion purchase of Pharmasset in 2011, roundly jeered as an overpay at the time, brought it sofosbuvir. But our minds jumped to politics. Shares closed Thursday at $9.60

Startup 40

Startup Study News Report 40